Medicus Pharma Ltd. To Participate In The Longwood Miami CEO ForumDr. Raza Bokhari, Executive Chairman & CEO will participate in panel discussions and highlight Company's AI-enabled Drug Development Strategy
American Lithium Minerals (OTC: AMLM) Targets Tokenized Commodities Opportunity Alongside MDCX, ASNS, EONR, ELPW Today!American Lithium Minerals Inc (OTC: AMLM ) is positioned in he global financial system is entering what many analysts describe as the next phase of asset digitization, where Real-World Asset (RWA) tokenization brings traditional commodities, infrastructure, and financial assets onto blockchain-based platforms. Industry forecasts from major financial institutions suggest that tokenized real-world assets could represent a multi-trillion-dollar market by the end of the decade , driven by demand for greater liquidity, transparency, and global accessibility in traditionally illiquid markets such as commodities and private assets.
Medicus Pharma on Bloomberg WorldDr. Raza Bokhari, Exec Chairman & CEO, Interviewed by Bloomberg Open Interest Anchor Matt Miller
New to The Street Broadcasts Tonight on Bloomberg Television at 6:30 PM EST - Shows 736, 737 and 738 Air Across the U.S., Latin America and MENANEW YORK CITY, NEW YORK / ACCESS Newswire / March 7, 2026 / New to The Street, one of the longest-running U.S. business television platforms spotlighting emerging growth companies and market innovation since 2009, will broadcast Shows 736, 737 and 738 tonight on Bloomberg Television at 6:30 PM EST. The programs will air across the United States, Latin America, and the Middle East & North Africa (MENA) as sponsored programming and will also be distributed digitally through the rapidly expanding New to The Street TV YouTube platform and NewsOut distribution network, which together reach more than 5 million subscribers worldwide.
Medicus Pharma To Participate in the 38th Annual Roth ConferenceCompany Exec. Chairman & CEO in a fireside chat is expected to highlight the role of Skinject in an autosomal dominant rare disease, AI-enabled drug development strategy and partnering readiness
New to The Street Signs Six-Part Media Series Featuring Medicus Pharma Ltd.NEW YORK CITY, NY / ACCESS Newswire / February 10, 2026 / New to The Street, the nationally syndicated, long-form television and digital media platform, today announced it has signed a six-part media series with Medicus Pharma Ltd. (
NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development program of novel and potentially disruptive therapeutics assets.
Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular RiskThe Company is developing Teverelix® as a best-in-class market product for advanced prostate cancer patients with high CV risk and a first in class product for Acute Urinary Retention Relapse prevention (AURr) collectively representing ~US$6 billion in potential market opportunity
Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development ProfileAmendment reduces and simplifies royalty structure on Teverelix® from ~4% to 2% while preserving global rights and IP control
Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026The Company enters 2026 with Multiple Phase 2 Catalysts, AI-enabled drug development strategy, and regulatory optionality as SKNJCT-003 study approaches database lock, topline clinical data readout and partnering readiness
Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in WomenThe Company’s abstract, Evaluation of Teverelix in Healthy Female Volunteers, has been accepted for presentation at American Association of Clinical Endocrinology (AACE) Annual meeting 2026
Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness AcceleratesThe Company enters 2026 with Multiple Phase 2 Catalysts collectively representing ~$8 billion in potential market opportunities, an AI-enabled development strategy, and regulatory optionality
Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics PlatformThe engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute urinary retention (AURr) and high CV risk prostate cancer collectively representing ~$6 billion in potential market opportunity
Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the SkinTHE COMPANY EXPECTS TO RELEASE TOPLINE RESULTS FOR SKNJCT-003 PHASE 2 CLINICAL TRIAL BEFORE THE END OF Q1 2026 AND REQUEST END-OF-PHASE 2 (EOP2) WITH THE FOOD AND DRUG ADMINISTRATION (FDA) IN H1 2026
